Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgrastim - SYGNIS Pharma

Drug Profile

Filgrastim - SYGNIS Pharma

Alternative Names: AX200; G-CSF - SYGNIS Pharma

Latest Information Update: 31 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Developer SYGNIS Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Amyotrophic lateral sclerosis
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Spinal cord injuries

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Spinal cord injuries; Stroke

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 25 Jul 2012 Discontinued - Preclinical for Amyotrophic lateral sclerosis in European Union (IV)
  • 25 Jul 2012 Discontinued - Preclinical for Spinal cord injuries in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top